We found that SRC-3 expression was elevated more in RR patients than in newly diagnosed MM patients, as well as in patients with disease progression; moreover, correlational analysis showed a significant negative correlation of SRC-3 with clinical outcomes, confirming the role of SRC-3 in tumor progression that previously has been reported by other groups. This evidence concerns the gene NCOA3 and Miyoshi myopathy.